Jul 1, 2020

lululemon acquires fitness startup MIRROR for $500mn

fitness
mindfulness
Tech
Startup
William Smith
2 min
Athletic apparel company lululemon has entered the health technology space with the acquisition of MIRROR
Athletic apparel company lululemon has entered the health technology space with the acquisition of MIRROR...

Athletic apparel company lululemon has entered the health technology space with the acquisition of MIRROR.

MIRROR operates an interactive workout platform with weekly live and thousands of on-demand classes in areas such as cardio, strength, yoga and boxing. Having launched in 2018, the company was founded by a former lululemon Ambassador.

The company’s technology involves the use of a mirror screen to show content which the user follows along to, in much the same vein as competitors such as Peloton.

lululemon framed the acquisition as part of its attempt to build an ecosystem of digital experiences, including exercise and mindfulness offerings. It had previously partnered with MIRROR via an initial investment in 2019 as well as a content partnership between the two brands.

In a press release, Calvin McDonald, lululemon’s chief executive officer, said: “In 2019, we detailed our vision to be the experiential brand that ignites a community of people living the sweatlife through sweat, grow and connect. The acquisition of MIRROR is an exciting opportunity to build upon that vision, enhance our digital and interactive capabilities, and deepen our roots in the sweatlife. We look forward to learning from and working with Brynn Putnam and the team at MIRROR to accelerate the growth of personalized in-home fitness.”

Mirror will continue as a standalone company within lululemon, while the transaction, remaining subject ot the usual conditions, is expected to close in Q2 of the 2020 financial year.

Brynn Putnam, founder and chief executive officer of MIRROR, said: “We are thrilled to officially become a part of the lululemon family. As part of lululemon, MIRROR can further strengthen its position and accelerate its growth by leveraging lululemon’s deep relationships with its guests, ambassadors and communities, as well as the company’s infrastructure, including its store network and ecommerce channels, to acquire new users.”

Share article

Jun 16, 2021

NHS opens 8 clinical trial sites to assess cancer treatment

NHS
Cancer
immunotherapy
MachineLearning
2 min
NHS and OncoHost to launch clinical trials analysing cancer patients response to immunotherapy

The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy. 

The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment.  They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities. 

Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.

OncoHost, an oncology startup,  will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®

“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.

“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient." 

"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”

Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.

Share article